BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32471990)

  • 1. Evolution and structure of clinically relevant gene fusions in multiple myeloma.
    Foltz SM; Gao Q; Yoon CJ; Sun H; Yao L; Li Y; Jayasinghe RG; Cao S; King J; Kohnen DR; Fiala MA; Ding L; Vij R
    Nat Commun; 2020 May; 11(1):2666. PubMed ID: 32471990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
    Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
    Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
    Sáez B; Martín-Subero JI; Lahortiga I; Largo C; Larrayoz MJ; Odero MD; Prosper F; Cigudosa JC; Siebert R; Calasanz MJ
    Cancer Genet Cytogenet; 2007 May; 175(1):65-8. PubMed ID: 17498561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
    Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
    Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel fusion transcripts in multiple myeloma.
    Lin M; Lee PL; Chiu L; Chua C; Ban KHK; Lin AHF; Chan ZL; Chung TH; Yan B; Chng WJ
    J Clin Pathol; 2018 Aug; 71(8):708-712. PubMed ID: 29453220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The landscape of long noncoding RNA-involved and tumor-specific fusions across various cancers.
    Guo M; Xiao ZD; Dai Z; Zhu L; Lei H; Diao LT; Xiong Y
    Nucleic Acids Res; 2020 Dec; 48(22):12618-12631. PubMed ID: 33275145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Noncoding RNA
    Handa H; Honma K; Oda T; Kobayashi N; Kuroda Y; Kimura-Masuda K; Watanabe S; Ishihara R; Murakami Y; Masuda Y; Tahara KI; Takei H; Kasamatsu T; Saitoh T; Murakami H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell myeloma.
    Lin P
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):709-27. PubMed ID: 19577166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V. Molecular classification and risk stratification of myeloma.
    Bergsagel PL; Chesi M
    Hematol Oncol; 2013 Jun; 31 Suppl 1(0 1):38-41. PubMed ID: 23775647
    [No Abstract]   [Full Text] [Related]  

  • 11. A molecular study of the t(4;14) in multiple myeloma.
    Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
    Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.
    Amin SM; Haugh AM; Lee CY; Zhang B; Bubley JA; Merkel EA; Verzì AE; Gerami P
    Am J Surg Pathol; 2017 Apr; 41(4):491-498. PubMed ID: 27776007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.
    Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2008 Jan; 80(1):31-6. PubMed ID: 18036184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
    Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
    Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
    Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
    Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
    Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance.
    Rasmussen T; Hudlebusch HR; Knudsen LM; Johnsen HE
    Br J Haematol; 2002 Jun; 117(3):626-8. PubMed ID: 12028033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.
    Wu SP; Pfeiffer RM; Ahn IE; Mailankody S; Sonneveld P; van Duin M; Munshi NC; Walker BA; Morgan G; Landgren O
    Clin Cancer Res; 2016 Aug; 22(16):4039-44. PubMed ID: 26847058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma.
    Xie Z; Gunaratne J; Cheong LL; Liu SC; Koh TL; Huang G; Blackstock WP; Chng WJ
    Oncotarget; 2013 Jul; 4(7):1008-18. PubMed ID: 23900284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
    Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
    Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.